Literature DB >> 1081023

Myasthenia gravis: studies on HL-A antigens and lymphocyte subpopulations in patients with myasthenia gravis.

L Hammarström, E Smith, E Möller, C Franksson, G Matell, G Von Reis.   

Abstract

Thirth-three patient with a clinical diagnosis of myasthenia gravis were tissue-typed for HL-A antigens. In agreement with earlier reports a significant increase in antigens HL-A1 and HL-A8 were found in this material. Two of the patients were treated with chronic thoracic duct drainage. Proportions of T and B lymphocytes in lymph and peripheral blood were estimated in these patients. In the lymph an initial decrease in the proportion of T cells occurred, which was accompanied by a subsequent increase in the proportion of B cells. Towards the end of the chronic drainage period this effect was reversed. A slightly different picture occurred in blood lymphocytes. Initially, there was an increase in both T and B cells, followed by a decrease in T-cells numbers in one patient, whereas in the second patient the proportion of T cells decreased from the onset of drainage while the proportion of B cells steadily increased. These studies showed that available markers for determination of T ANd B cells were useful for studies of lymphocyte subpopulations in blood and lymph. Lmyphocytes from the thoracic duct were also tested for their reactivity to various mitogens specific for either T or B cells. The B-cell mitogens which were used were dextran sulphate, lipopolysaccharide, purified protein derivative, as well as rabbit anti-human beta2-microglobulin serum. The T-cell mitogens investigated were concanavalin A and phytohaemagglutinin. No significant differences in the responsiveness of thoracic duct lymphocytes compared to normal peripheral blood lymphocytes were found.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1081023      PMCID: PMC1538268     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  41 in total

1.  MULTIPLE ANTIBODY PRODUCTION IN MYASTHENIA GRAVIS.

Authors:  H VAN DER GELD; T E FELTKAMP; J VAN LOGHEM; H J OOSTERHUIS; A BIEMOND
Journal:  Lancet       Date:  1963-08-24       Impact factor: 79.321

2.  An evaluation of thymectomy in myasthenia gravis.

Authors:  J A SIMPSON
Journal:  Brain       Date:  1958-03       Impact factor: 13.501

Review 3.  Correlation between histocompatibility antigens and susceptibility to illness.

Authors:  J Dausset
Journal:  Prog Clin Immunol       Date:  1972

4.  Letter: Immune response genes in myasthenia gravis.

Authors:  P O Behan; J A Simpson; H Dick
Journal:  Lancet       Date:  1973-11-03       Impact factor: 79.321

5.  Histocompatibility antigens associated with adult coeliac disease.

Authors:  P L Stokes; P Asquith; G K Holmes; P Mackintosh; W T Cooke
Journal:  Lancet       Date:  1972-07-22       Impact factor: 79.321

6.  HL-A and disordered immunity.

Authors:  A C White; R S Barnetson; J A Costa; D B McClelland
Journal:  Lancet       Date:  1973-01-13       Impact factor: 79.321

7.  Association of autoimmune active chronic hepatitis with HL-A1,8.

Authors:  I R Mackay; P J Morris
Journal:  Lancet       Date:  1972-10-14       Impact factor: 79.321

8.  HL-A antigens and susceptibility to diseases. A study of patients with acute lymphoblastic leukaemia, Hodgkin's disease, and childhood asthma.

Authors:  E Thorsby; A Engeset; S O Lie
Journal:  Tissue Antigens       Date:  1971

9.  Renal potassium wasting in hypercalcaemia.

Authors:  P H Sanderson
Journal:  Br Med J       Date:  1967-03-18

10.  Immunization of dissociated spleen cell cultures from normal mice.

Authors:  R I Mishell; R W Dutton
Journal:  J Exp Med       Date:  1967-09-01       Impact factor: 14.307

View more
  4 in total

1.  Immunological findings in immunoblastic lymphadenopathy. A detailed case study.

Authors:  J M Kreisler; E Moreno; I Moneo; A Bootello; E Bouza; J M De Letona; A Anaya
Journal:  Clin Exp Immunol       Date:  1977-03       Impact factor: 4.330

2.  Clinical and immunological associations in myasthenia gravis. 2. Cell-mediated immunity.

Authors:  H J Sagar; G A Davies-Jones; I D Allonby
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-11       Impact factor: 10.154

3.  Lymphocyte function in myasthenia gravis.

Authors:  S Kawanami; A Kanaide; Y Itoyama; Y Kuroiwa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-08       Impact factor: 10.154

4.  Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population.

Authors:  Angelina H Maniaol; Ahmed Elsais; Åslaug R Lorentzen; Jone F Owe; Marte K Viken; Hanne Sæther; Siri T Flåm; Geir Bråthen; Margitta T Kampman; Rune Midgard; Marte Christensen; Anna Rognerud; Emilia Kerty; Nils Erik Gilhus; Chantal M E Tallaksen; Benedicte A Lie; Hanne F Harbo
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.